Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.

Latest From Francesca Bruce

Smaller EU Countries Call for More Comparative Trials

More should be done to incentivize comparative clinical trials so as to allow better decisions on drug pricing to be taken, said Austria’s representative at a recent meeting of EU health ministers.

Europe Belgium

Nordic Countries To Agree Closer Collaboration On Joint Price Negotiation and Procurement

Five Nordic countries are agreeing a common strategy for closer collaboration on access to hospital drugs.

Europe Denmark

England: Shionogi And Pfizer Ink ‘World First’ Payment Model Deal For Antibiotics

Shionogi and Pfizer have formally agreed to a scheme that offers companies a new and sustainable payment model for innovating in antibiotics.

Europe International

Dutch Orphan Drugs Pilot Promises Quicker Access and Lower Prices

Companies are initially expected to fund drugs for individual patients under a Dutch pilot for improving access to orphan drugs.

Europe Netherlands

Scotland: Are Orphan Medicines Over Incentivized?

Over the years, pharmaceutical companies in Europe have been given more incentives to develop orphan drugs, such as 10 years of market exclusivity. But with numbers of orphans on the rise, has the pendulum swung the other way?

United Kingdom Europe

England Launches Innovative Medicines Fund

The new financing mechanism promises faster access to new treatments, but some industry concerns remain unresolved.

Europe United Kingdom
See All
UsernamePublicRestriction

Register